🇮🇳*Business News Headlines*🇮🇳
*Economic Times*
Ø JSPL plans over Rs 1 lakh crore investment in Odisha in next 10 years
Ø Lenders discuss option to invite fresh bids for RCom's assets with resolution professional
Ø Tata Steel sees 73% of biz from India over 10 years
Ø Tata Power shareholders approve reappointment of N Chandrasekaran as director
Ø NSE-BSE bulk deals: Texas retirement fund buys stake in H.G. Infra
Ø Chip shortage to affect Tata Motors' near-term profitability
Ø Piramal Capital to raise up to Rs 1,000 crore via NCDs
Ø Reliance Infra gets shareholders nod to raise up to Rs 551 cr via preferential allotment
Ø Sebi seeks info on trades by execs of big cos where promoters hiked stake
Ø DHFL resolution: NCLAT issues notices to lenders, Piramal on 63 Moons Tech's plea
Ø Tycoon Gautam Adani seeks $1 billion to refinance Mumbai airport debt
*Business Standard*
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Matrimony.com to buy wedding planning firm ShaadiSaga for Rs 11 cr
Ø JSPL announces over Rs 1 trillion investment in Odisha in next 10 years
Ø Private banks' loan books shrink in Q1 amid second wave of Covid-19
Ø NCLAT issues notices to lenders, Piramal on 63 Moons Technologies' plea
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Edtech firm upGrad earmarks $250 mn for M&A, non-linear growth
Ø Vedanta's funding ops to improve on raising debt cap at subsidiary: S&P
Ø Bajaj Finance books fewer new loans in June quarter over March
Ø Govt's move to bring DPE under FinMin to aid privatisation process
*Financial Express*
Ø Fitch cuts India growth forecast to 10 pc, says rapid vaccination to support revival
Ø Cabinet Reshuffle 2021: From Health Minister Harsh Vardhan to MoS Babul Supriyo, 12 union ministers lose cabinet berths
Ø Info Edge reduces OFS size in Zomato IPO by half
Ø Increasing imports of tea a matter of great concern
Ø Sebi levies nearly Rs 23 lakh fine on 16 entities
Ø Some states to roll out labour reforms in 3-5 months
Ø Indian IT industry to post strong recovery with 11% revenue growth in FY22: Crisil
Ø Sebi cuts time period for filing application to obtain NOC for release of 1 pc of issue amount
Ø CapitaLand launches Rs 2,250 cr fund to develop logistics parks in India
Ø RBI notifies inclusion of retail, wholesale trade under MSME category
*Mint*
Ø PNB tells housing arm to propose fresh plan, reconsider ₹4,000 cr Carlyle deal
Ø Coal shows its staying power as economies bounce back
Ø Cabinet reshuffle: PM Modi meets BJP MPs ahead of rejig
Ø Paytm reshuffles board before floating mega IPO
Ø JK Tyre collaborates with Hyundai Motor for its new vehicle Alcazar
Ø Investment advisors cannot take power of attorney from clients: Sebi
Ø Indian banks to see bad loans peaking post FY23: Fitch
Ø Tata Power sets up fast EV charging station at Statue of Unity, Gujarat
Ø Clean Science and Technology's favourable financials reflect in IPO valuations
Ø ‘India will contribute to being an engine of growth for global economy’
Ø India's domestic traffic was 71% lower in May 2021 compared to May 2019: IATA
*Economic Times*
Ø JSPL plans over Rs 1 lakh crore investment in Odisha in next 10 years
Ø Lenders discuss option to invite fresh bids for RCom's assets with resolution professional
Ø Tata Steel sees 73% of biz from India over 10 years
Ø Tata Power shareholders approve reappointment of N Chandrasekaran as director
Ø NSE-BSE bulk deals: Texas retirement fund buys stake in H.G. Infra
Ø Chip shortage to affect Tata Motors' near-term profitability
Ø Piramal Capital to raise up to Rs 1,000 crore via NCDs
Ø Reliance Infra gets shareholders nod to raise up to Rs 551 cr via preferential allotment
Ø Sebi seeks info on trades by execs of big cos where promoters hiked stake
Ø DHFL resolution: NCLAT issues notices to lenders, Piramal on 63 Moons Tech's plea
Ø Tycoon Gautam Adani seeks $1 billion to refinance Mumbai airport debt
*Business Standard*
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Matrimony.com to buy wedding planning firm ShaadiSaga for Rs 11 cr
Ø JSPL announces over Rs 1 trillion investment in Odisha in next 10 years
Ø Private banks' loan books shrink in Q1 amid second wave of Covid-19
Ø NCLAT issues notices to lenders, Piramal on 63 Moons Technologies' plea
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Edtech firm upGrad earmarks $250 mn for M&A, non-linear growth
Ø Vedanta's funding ops to improve on raising debt cap at subsidiary: S&P
Ø Bajaj Finance books fewer new loans in June quarter over March
Ø Govt's move to bring DPE under FinMin to aid privatisation process
*Financial Express*
Ø Fitch cuts India growth forecast to 10 pc, says rapid vaccination to support revival
Ø Cabinet Reshuffle 2021: From Health Minister Harsh Vardhan to MoS Babul Supriyo, 12 union ministers lose cabinet berths
Ø Info Edge reduces OFS size in Zomato IPO by half
Ø Increasing imports of tea a matter of great concern
Ø Sebi levies nearly Rs 23 lakh fine on 16 entities
Ø Some states to roll out labour reforms in 3-5 months
Ø Indian IT industry to post strong recovery with 11% revenue growth in FY22: Crisil
Ø Sebi cuts time period for filing application to obtain NOC for release of 1 pc of issue amount
Ø CapitaLand launches Rs 2,250 cr fund to develop logistics parks in India
Ø RBI notifies inclusion of retail, wholesale trade under MSME category
*Mint*
Ø PNB tells housing arm to propose fresh plan, reconsider ₹4,000 cr Carlyle deal
Ø Coal shows its staying power as economies bounce back
Ø Cabinet reshuffle: PM Modi meets BJP MPs ahead of rejig
Ø Paytm reshuffles board before floating mega IPO
Ø JK Tyre collaborates with Hyundai Motor for its new vehicle Alcazar
Ø Investment advisors cannot take power of attorney from clients: Sebi
Ø Indian banks to see bad loans peaking post FY23: Fitch
Ø Tata Power sets up fast EV charging station at Statue of Unity, Gujarat
Ø Clean Science and Technology's favourable financials reflect in IPO valuations
Ø ‘India will contribute to being an engine of growth for global economy’
Ø India's domestic traffic was 71% lower in May 2021 compared to May 2019: IATA
*Pharmaceuticals*
*Strong Growth momentum to sustain*
*Q1FY2022 Results Preview*
*Sector: Pharmaceuticals*
*Sector View: Positive*
Pharmaceutical companies in Sharekhan’s universe are expected to report strong performance for Q1FY2022 on a y-o-y basis, driven by a sturdy performance of the domestic business. The performance of the companies is expected to be reflective of the strong growth in the Indian Pharmaceutical Markets (IPM) in Q1FY22 largely attributable to a low base in the corresponding quarter of the previous year coupled with a revival in acute therapies – anti-infective, pain / analgesics amongst others. Also the VMN (Vitamins/ Minerals/ Nutrients) space grew in strong double digits.
*Outlook*
*Growth levers intact:* Indian pharmaceutical companies are better placed to harness opportunities and post healthy growth going ahead. Indian companies are among the most competitive globally and hold a sizeable market share in most developed as well as other markets. Indian pharmaceutical companies have developed strong capabilities over the years, which are depicted in their inherent strength.
*Valuation*
*Sector view - Positive:* The pharma index had largely underperformed the benchmark indices, considering a longer tenure from around April 2015 till date. However, in a little over a year, the Nifty Pharma index had bucked its trend and outperformed the benchmark, reporting a sturdy 76% return as compared to ~32% return by the benchmark. Strong outperformance is expected to continue going ahead as well and we see this as the beginning of a multi-year bull run for pharmaceutical companies.
*Key Risks* 1) Adverse regulatory changes / delay in approvals could impact the sector’s performance. 2) Currency volatility could dent earnings.
*Leaders:* Laurus Labs, Sun Pharmaceutical Industries, Solara Active Pharma Science
*Laggards:* Shilpa Medicare, IPCA Laboratories
*Preferred Picks* Large Caps: Aurobindo, Cadila, Lupin, Dr Reddy’s, Sun Pharma, Biocon
Mid Caps: Gland Pharma, Laurus Labs, Strides Pharma Sciences, Solara Active Pharma Science, Abbott India, Caplin Point Laboratories
*Strong Growth momentum to sustain*
*Q1FY2022 Results Preview*
*Sector: Pharmaceuticals*
*Sector View: Positive*
Pharmaceutical companies in Sharekhan’s universe are expected to report strong performance for Q1FY2022 on a y-o-y basis, driven by a sturdy performance of the domestic business. The performance of the companies is expected to be reflective of the strong growth in the Indian Pharmaceutical Markets (IPM) in Q1FY22 largely attributable to a low base in the corresponding quarter of the previous year coupled with a revival in acute therapies – anti-infective, pain / analgesics amongst others. Also the VMN (Vitamins/ Minerals/ Nutrients) space grew in strong double digits.
*Outlook*
*Growth levers intact:* Indian pharmaceutical companies are better placed to harness opportunities and post healthy growth going ahead. Indian companies are among the most competitive globally and hold a sizeable market share in most developed as well as other markets. Indian pharmaceutical companies have developed strong capabilities over the years, which are depicted in their inherent strength.
*Valuation*
*Sector view - Positive:* The pharma index had largely underperformed the benchmark indices, considering a longer tenure from around April 2015 till date. However, in a little over a year, the Nifty Pharma index had bucked its trend and outperformed the benchmark, reporting a sturdy 76% return as compared to ~32% return by the benchmark. Strong outperformance is expected to continue going ahead as well and we see this as the beginning of a multi-year bull run for pharmaceutical companies.
*Key Risks* 1) Adverse regulatory changes / delay in approvals could impact the sector’s performance. 2) Currency volatility could dent earnings.
*Leaders:* Laurus Labs, Sun Pharmaceutical Industries, Solara Active Pharma Science
*Laggards:* Shilpa Medicare, IPCA Laboratories
*Preferred Picks* Large Caps: Aurobindo, Cadila, Lupin, Dr Reddy’s, Sun Pharma, Biocon
Mid Caps: Gland Pharma, Laurus Labs, Strides Pharma Sciences, Solara Active Pharma Science, Abbott India, Caplin Point Laboratories
*Consumer Goods*
*Agile supply chain to moderate impact of the second wave*
*Q1FY2022 Results Preview*
*Sector: Consumer Goods*
*Sector View: Positive*
Consumer goods companies under Sharekhan’s coverage universe are likely to post double-digit revenue growth of 11-30%, led by agile supply chain aiding products to remain available on store shelves, resilient demand, and low base of corresponding quarter last year. Double-digit revenue growth will largely be driven by mix of volume and price increases (undertaken to pass on raw-material inflation). Q1FY2021 was badly affected by stringent lockdown norms, affecting manufacturing and supply of products during the first 45 days of the quarter.
*Outlook*
*Demand remains resilient; Margins to improve sequentially* Pre-quarter commentary of most consumer goods companies indicated strong sales recovery from June 2021 with easing of lockdown restrictions in most parts of the country. Demand, which started recovering from Q3FY2021, remained resilient in Q1FY2022. With expected normal monsoon for the third consecutive year, agri production is predicted to be better in Kharif season 2021.
*Valuation*
The consumer goods sector saw fast recovery compared to some of the other sectors in the pandemic environment. In the large-cap space, we continue to like HUL and Asian Paints as both companies are market leaders in key categories, have strong distribution reach to cater to improving demand, and sturdy balance sheet to lead its innovation strategy.
*Key risks:* Increased competition in some of the high penetrated categories and sustained spike in key input prices would act as key risks to the performance of consumer goods companies.
*Q1FY2022 leaders:* Asian Paints, GCPL, Colgate, ITC, and Globus Spirits.
*Q1FY2022 Laggards:* Tata Consumer products, Britannia Industries, Jyothy Labs and Bajaj Consumer Care.
*Preferred picks:* Asian Paints, Hindustan Unilever, Godrej Consumer Products, Marico, and Tata Consumer Products.
*Agile supply chain to moderate impact of the second wave*
*Q1FY2022 Results Preview*
*Sector: Consumer Goods*
*Sector View: Positive*
Consumer goods companies under Sharekhan’s coverage universe are likely to post double-digit revenue growth of 11-30%, led by agile supply chain aiding products to remain available on store shelves, resilient demand, and low base of corresponding quarter last year. Double-digit revenue growth will largely be driven by mix of volume and price increases (undertaken to pass on raw-material inflation). Q1FY2021 was badly affected by stringent lockdown norms, affecting manufacturing and supply of products during the first 45 days of the quarter.
*Outlook*
*Demand remains resilient; Margins to improve sequentially* Pre-quarter commentary of most consumer goods companies indicated strong sales recovery from June 2021 with easing of lockdown restrictions in most parts of the country. Demand, which started recovering from Q3FY2021, remained resilient in Q1FY2022. With expected normal monsoon for the third consecutive year, agri production is predicted to be better in Kharif season 2021.
*Valuation*
The consumer goods sector saw fast recovery compared to some of the other sectors in the pandemic environment. In the large-cap space, we continue to like HUL and Asian Paints as both companies are market leaders in key categories, have strong distribution reach to cater to improving demand, and sturdy balance sheet to lead its innovation strategy.
*Key risks:* Increased competition in some of the high penetrated categories and sustained spike in key input prices would act as key risks to the performance of consumer goods companies.
*Q1FY2022 leaders:* Asian Paints, GCPL, Colgate, ITC, and Globus Spirits.
*Q1FY2022 Laggards:* Tata Consumer products, Britannia Industries, Jyothy Labs and Bajaj Consumer Care.
*Preferred picks:* Asian Paints, Hindustan Unilever, Godrej Consumer Products, Marico, and Tata Consumer Products.
Market Wizard
Short Term Super Duper Aggressive Bumper Call Buy Emami Papers at CMP of 153.6 - 155 and dips still 147 Sl 144 Targets:- 157 - 159 - 162 - 165 - 168 - 172+ Above that we can see 177 - 183 - 190+ Disclaimer:- I am not SEBI Registered. Please consult your…
EMAMI PAPERS 196.4❤️❤️
NEW 52 WEEK HIGH
NEW 52 WEEK HIGH
Market Wizard
Short Term Super Duper Aggressive Bumper Call Buy Emami Papers at CMP of 153.6 - 155 and dips still 147 Sl 144 Targets:- 157 - 159 - 162 - 165 - 168 - 172+ Above that we can see 177 - 183 - 190+ Disclaimer:- I am not SEBI Registered. Please consult your…
EMAMI PAPERS 202.8❤️❤️
NEW 52 WEEK HIGH
NEW 52 WEEK HIGH
Market Wizard
Super Duper Bumper Call Buy National Plastic Technology (BSE - 531287) at CMP of 40.4 - 41.5 and on dips till 36 Sl 35 Targets:- 43 - 44- 45 - 46 - 47 - 48 + Above 48 we can see 52 - 55+ Long Term Target:- 100 - 130 - 160+ Disclaimer:- I am not SEBI Registered.…
NATIONAL PLASTIC TECHNOLOGY 68❤️❤️
NEW 52 WEEK HIGH
NEW 52 WEEK HIGH
Mid Term Bumper Call
Buy Vedavaag System (BSE - 533056) at CMP of 42 - 43 (Upper Circuit Levels) and dips till 39
Sl 37
Targets:- 46 - 47 - 48 - 49 - 50+
Above that we can see 54 - 57 - 61+
Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.
Stock will rally Circuit to Circuit ✈️✈️✈️
Buy Vedavaag System (BSE - 533056) at CMP of 42 - 43 (Upper Circuit Levels) and dips till 39
Sl 37
Targets:- 46 - 47 - 48 - 49 - 50+
Above that we can see 54 - 57 - 61+
Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.
Stock will rally Circuit to Circuit ✈️✈️✈️
Market Wizard
Mid Term Bumper Call Buy Vedavaag System (BSE - 533056) at CMP of 42 - 43 (Upper Circuit Levels) and dips till 39 Sl 37 Targets:- 46 - 47 - 48 - 49 - 50+ Above that we can see 54 - 57 - 61+ Disclaimer:- I am not SEBI Registered. Please consult your financial…
Added 11k Vedavaag at avg of 42.44
Market Wizard
Short Term Bumper Fundamental Call Buy Bajaj Steel (BSE - 507944) at cmp of 592 - 596 and dips till 570 Sl 555 Short Term Targets:- 600 - 603 - 606 - 610 - 614 - 618 - 625+ Above 625 we can see 645 - 660+ Disclaimer:- I am not SEBI Registered. Please consult…
BAJAJ STEEL 1287❤️❤️❤️
NEW 52 WEEK HIGH
NEW 52 WEEK HIGH